The University of Texas MD Anderson Cancer Center (US)
Access 250+ million papers and cite this researcher's work with AI assistance
H-index
191
Publications
2569
Citations
154055
i10-index
1108
Want to find and read papers by this researcher? AnswerThis gives you instant access.
Sign Up Free| Title | Year | Citations |
|---|---|---|
Response to Neoadjuvant Therapy and Long-Term Surv... | 2008 | 2899 |
Everolimus in Postmenopausal Hormone-Receptor–Posi... | 2011 | 2860 |
Ribociclib as First-Line Therapy for HR-Positive, ... | 2016 | 2028 |
Breast Cancer Molecular Subtypes Respond Different... | 2005 | 1894 |
PTEN activation contributes to tumor inhibition by... | 2004 | 1862 |
Future of Cancer Incidence in the United States: B... | 2009 | 1730 |
Measurement of Residual Breast Cancer Burden to Pr... | 2007 | 1662 |
Prognostic and predictive value of the 21-gene rec... | 2009 | 1412 |
Clinical Course of Breast Cancer Patients With Com... | 1999 | 1337 |
Tucatinib, Trastuzumab, and Capecitabine for HER2-... | 2019 | 1323 |
Gabriel N. Hortobágyi is a researcher with 2569 publications and 154055 citations. They are affiliated with The University of Texas MD Anderson Cancer Center. Their research focuses on . With an h-index of 191, they are among the top researchers in their field.
Distribution of citations across publications
AnswerThis uses AI to help you search, understand, and cite research from Gabriel N. Hortobágyi and 250M+ other papers.
Citations per publication by year